CICC: Maintains outperform rating on Hugel-Bio (06990.HK) with a target price of HKD 550.

According to the Zhitong Finance APP, CICC released a research report stating that, considering the first payment of authorization income of Kelun Botai Bio-B (06990.HK), the basic net profit forecast for 2026 remains unchanged. The bank maintains an outperform rating and a target price of HK$550 based on the DCF model, representing a 33.4% upside potential compared to the current stock price.